New Entamoeba Histolytica Monoclonal Antibodies

August 14, 2017 PR-M08-17-NI-001

E. histolytica is an anaerobic parasite that causes amoebic dysentery.

It infects humans and other primates via the fecal oral route. Symptoms include abdominal pain, bloodydiarrhea and weight loss. It can result in intestinal lesions and liver abscesses.

ViroStat has just released a set of new mouse monoclonal antibodies to E. histolytica. These new antibodies function in ELISA and lateral flow applications and thus serve as excellent tools for the detection of this parasite.


About ViroStat, Inc. 

ViroStat, Inc. is a primary manufacturer of infectious disease antigens and antibodies, supplying researchers and manufacturers since 1985. Specialties include high affinity antibodies to Flu A, Flu B, RSV & Strep A for use in rapid lateral flow devices as well as antibodies to food-borne pathogens and toxins. Also, many specificities to HCV, HBV, CMV & EBV for use in anti-viral HTS assays.

Contact

ViroStat, Inc.
PO Box 8522
Portland, ME 04104 USA
Phone: +1 207 856 6620
E-mail: info@virostat-inc.com
Web: www.virostat-inc.com

 

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

ViroStat, Inc.

ViroStat was founded in 1985 by Dr. Douglas McAllister to provide infectious disease antibody tools to researchers and manufacturers. These include the areas of virology, bacteriology and parasitology. Applications for these include detection of respiratory agents, STD agents, gastrointestinal agents/toxins and food borne pathogens. The company offers more than 500 infectious disease reagents including their MONOTOPE" monoclonal antibodies, OMNITOPE" polyclonal antibodies and numerous recombinant antigens. Many of these antibodies are used by manufacturers of rapid, point of care tests currently made and sold in the US.

Q: